Welcome to our dedicated page for Collegium Pharmaceutical news (Ticker: COLL), a resource for investors and traders seeking the latest updates and insights on Collegium Pharmaceutical stock.
News about Collegium Pharmaceutical, Inc. (Nasdaq: COLL) focuses on its activities as a biopharmaceutical company with a portfolio spanning responsible pain management and neuropsychiatry. The company regularly issues press releases on product-related research, financial performance, capital structure, and corporate initiatives, providing investors and healthcare professionals with insight into its operations.
A major theme in Collegium’s news flow is the development and commercialization of JORNAY PM, a central nervous system stimulant indicated for the treatment of ADHD in people 6 years of age and older. The company highlights real-world data on JORNAY PM at scientific meetings such as the American Professional Society of ADHD and Related Disorders (APSARD), the American Academy of Child & Adolescent Psychiatry, and the Neuroscience Education Institute conferences. Releases describe poster presentations on dosing, comparative outcomes versus other ADHD treatments, and changes in functioning and psychiatric symptoms in various patient groups.
Collegium also issues news on its pain portfolio, including BELBUCA and XTAMPZA ER. At events like PAINWeek, the company presents multiple posters that examine treatment characteristics, safety, economic burden, and clinical outcomes for patients with chronic pain. These communications underscore Collegium’s focus on responsible pain management and real-world evidence generation.
Investors following COLL can find regular updates on quarterly financial results, guidance, and non-GAAP metrics such as adjusted EBITDA in the company’s earnings press releases. Additional news covers capital deployment, including share repurchase authorizations and the closing of a syndicated credit facility, as well as participation in healthcare and investor conferences. For those tracking developments in ADHD treatment and opioid-based pain therapies, the Collegium news page offers an organized view of clinical data, commercial progress, and financial disclosures over time.
Collegium Pharmaceutical (COLL) announced significant changes to its Board of Directors and executive leadership team. Founder and Chairman Michael Heffernan and Board Member Gwen A. Melincoff will retire at the Annual General Meeting on May 15, 2025. Gino Santini, current Lead Independent Director, will become Chairman, while Dr. Carlos Paya will be nominated to the Board.
The company also appointed three new executive leaders: David Dieter as Executive VP and General Counsel, Jane Gonnerman as Executive VP of Strategy and Corporate Development, and Dean J. Patras as Chief People Officer. These appointments come as Collegium enters a new growth phase focused on accelerating momentum for Jornay PM, maximizing its pain portfolio, and strategic capital deployment.
Collegium Pharmaceutical (Nasdaq: COLL) announced two poster presentations featuring real-world data for its ADHD treatment Jornay PM (methylphenidate HCl) at the National Association of Pediatric Nurse Practitioners (NAPNAP) 46th National Conference in Chicago from March 10-13, 2025.
The presentations, which will showcase real-world benefits of Jornay PM as a therapeutic option for the ADHD community, will be displayed in the Riverside Center Exhibit Hall during specific exhibition hours on March 10-11, 2025. Chief Medical Officer Thomas Smith emphasized the company's commitment to providing differentiated medicines for serious medical conditions.
The PR highlights that ADHD is one of the most common childhood psychiatric conditions, typically diagnosed in childhood and potentially continuing into adulthood, with symptoms including attention difficulties, impulsive behaviors, and hyperactivity, particularly during early morning routines.
Collegium Pharmaceutical (Nasdaq: COLL) has announced its upcoming participation in three major healthcare investor conferences in March 2025. The company's management will engage in investor meetings at the Leerink Partners 2025 Global Healthcare Conference on March 11, the Jefferies Biotech on the Beach Summit on March 12, and the Barclays 27th Annual Global Healthcare Conference on March 13.
Collegium Pharmaceutical reported strong financial results for Q4 and full-year 2024. The company achieved record quarterly revenue of $181.9 million (up 22% YoY) and full-year revenue of $631.4 million (up 11% YoY). Q4 GAAP net income was $12.5 million with record adjusted EBITDA of $107.7 million.
Key product performance included Jornay PM with Q4 net revenue of $29.3 million and pro forma full-year revenue of $100.7 million, showing 29% YoY prescription growth. Belbuca achieved record quarterly revenue of $55.2 million (up 12% YoY), while Xtampza ER posted record revenue of $51.5 million (up 6% YoY).
The company ended 2024 with $162.8 million in cash and equivalents, after completing the $200 million Ironshore Therapeutics acquisition and executing $60 million in share repurchases.
Collegium Pharmaceutical (Nasdaq: COLL) has scheduled its fourth quarter and full-year 2024 financial results announcement for Thursday, February 27, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. ET on the same day to discuss the results. Investors can access the call via U.S. dial-in (877) 407-8037 or International dial-in (201) 689-8037. An audio webcast will be available on the company's website investor section and will remain accessible for replay approximately two hours after the event.
Collegium Pharmaceutical (Nasdaq: COLL) has appointed Nancy S. Lurker to its Board of Directors, effective February 4, 2025. Lurker brings significant expertise in commercial growth and strategic acquisitions, having most recently served as President and CEO of EyePoint Pharmaceuticals until 2023, where she now holds the position of Executive-Vice Chair.
Her extensive experience includes roles as President and CEO of PDI, Senior Vice President and Chief Marketing Officer of Novartis Pharmaceuticals, and President and CEO of ImpactRx. She currently serves on multiple boards, including Alkermes plc and Altasciences, , and advisory boards for Novo Holdings and Stanford Medicine's Master of Science program.
Collegium Pharmaceutical (Nasdaq: COLL) has announced its 2025 financial guidance, projecting product revenues between $735-750 million and adjusted EBITDA of $435-450 million. The company expects Jornay PM, their ADHD treatment, to generate over $135 million in net revenue, positioning it as their primary growth driver.
The company's adjusted operating expenses are anticipated to be between $220-230 million. Recent highlights include completing the Ironshore integration, accelerating Jornay PM prescriptions during the 2024 back-to-school season, and executing a share repurchase program worth $60 million under a $150 million authorization, including $25 million in Q4 2024 and $35 million through an accelerated program in May 2024.
Collegium Pharmaceutical (Nasdaq: COLL) has announced its participation in two upcoming investor conferences. The company will engage in fireside chats at the Jefferies London Healthcare Conference on November 19, 2024, at 1:30 p.m. GMT and the Piper Sandler 36th Annual Healthcare Conference on December 5, 2024, at 1:00 p.m. ET. Both sessions will be accessible via webcast through the company's investor relations website, with recordings available for 90 days post-presentation.
Collegium Pharmaceutical reported strong Q3 2024 financial results with record net revenue of $159.3 million, up 17% year-over-year. The growth was driven by record revenues from Belbuca ($53.2M) and Xtampza ER ($49.5M). The company achieved GAAP net income of $9.3 million and record adjusted EBITDA of $105.1 million, up 18% year-over-year. A significant development was the acquisition of Ironshore Therapeutics, expanding into neurology with Jornay PM, which is expected to generate over $100 million in pro forma net revenue in 2024. The company reaffirmed its 2024 guidance with projected product revenues of $620-635 million.
Collegium Pharmaceutical (COLL) has appointed Vikram Karnani as President and CEO, effective November 12, 2024. Karnani brings over 15 years of life sciences leadership experience, notably from Horizon Therapeutics where he helped grow annual net product sales from $300 million to nearly $4 billion. He succeeds interim CEO Michael Heffernan, who will remain Board Chairman.
The appointment comes as Collegium's pain portfolio achieves record revenue, with Jornay PM positioned as the lead growth driver. Karnani most recently served as Executive VP and President of Global Commercial Operations and Medical Affairs (Rare Disease) at Amgen, following its acquisition of Horizon in 2023.
FAQ
What is the current stock price of Collegium Pharmaceutical (COLL)?
What is the market cap of Collegium Pharmaceutical (COLL)?
